Carlton South Vic 3053, Australia
Go to Investors Hub
info@radiopharmtheranostics.com

Radiopharm Theranostics Achieves Confirmed Durable PartialResponse in Ongoing Phase 1 Trial of RAD204 in Patients withAdvanced Solid Tumors Post-Immunotherapy

Loading Viewer…

Leave a Reply

Your email address will not be published.Required fields are marked *

More Announcements & Updates

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
aVb6 Integrin (RAD301) IND approval for Phase 1 trial
FDA grants pediatric disease designation for DUNP19-revised
Categories
Announcements
Announcements
Annual Reports
Annual Reports
Presentations
Presentations
News
News
Recent News
Analyst ReportsAnnouncementsAnnual ReportsInvestor PresentationsRAD ArticlesUpdates
Tags
Tags
Appendix 2A (1) Appendix 3B (1) Change of Director's Interest Notice (1) Cleansing Notice (1) PDF (26) Periodic Reports (24) Price Sensitive (84) Progress Report (2) Video (3) With Summary (2) With Video (4)
Archives
Archives
RSS RSS
Close
Search

Hit enter to search or ESC to close

cookie By using this website, you agree to our cookie policy. Close